Thermal Ablation Extends Lung Cancer Patients' Lives

During thermal ablation, an interventional radiologist utilized imaging to guide a small needle through the skin into the tumor. Energy was then transmitted to the tip of the needle to heat and destroy the tumor with heat or freeze it with cold.

"Only one-third of patients diagnosed with non-small cell lung cancer are eligible for surgery--the rest face the reality of having less than 12 months to live,” stated lead author of the study, Damian Dupuy, M.D., from Rhode Island Hospital (Providence, USA; www.lifespan.org). "These new outpatient treatments not only are effective, but allow us to treat patients who historically have no other options. Utilizing imaging and targeted thermal ablation, we can heat and destroy lung tumors, and extend a patient's life. As a physician, it's so gratifying to be able to provide a treatment that is so beneficial to patients and so easy for them to undergo.”

The purpose of this study, published in the July 2006 issue of the Journal of Vascular and Interventional Radiology (JVIR), was to assess the clinical outcomes of patients with early-stage NSCLC after combined treatment with thermal ablation and radiotherapy, and it demonstrated that the combination therapy may result in an improved survival over either modality alone.

The patients in the study were terminal, with a life expectancy of less than one year, and were not surgical candidates according to the oncology team which consisted of a pulmonologist, medical oncologist, radiation oncologist, and thoracic surgeon. Twenty-seven of the patients who underwent thermal ablation subsequently received external-beam radiation, the primary treatment in patients who are considered poor operative candidates. Fourteen patients underwent thermal ablation followed by interstitial brachytherapy, which is radiation therapy given internally to the tumor with a catheter. Of the 41 patients, 97.6% survived to six months, 86.8% to one year, 70.4% to two years and 57.1% to three years. The median follow-up was 19.5 months with an average survival of 42.2 months. The patients with tumors smaller than 3 cm (n = 17) had the best outcomes, with an average survival of 44.4 months.

Thermal ablation can be given without affecting the patient's overall health and most people can resume their usual activities in a few days. The treatment typically does not require general anesthesia and is usually performed on an outpatient basis. Thermal ablation treatments are a growing area in interventional oncology, a specialty area of medicine within interventional radiology. In this study, the two types of thermal ablation used were radiofrequency and microwave.

Radiofrequency ablation (RFA) provides a non-surgical, localized treatment that kills the tumor cells with heat, while sparing the healthy lung tissue. During the procedure, the interventional radiologist guides a small needle through the skin into the tumor. From the tip of the needle, radiofrequency energy is transmitted to the tip of the needle, where it produces heat in the tissues. The dead tumor tissue shrinks and slowly forms a scar. In a small number of cases, RFA can extend patients' lives, but it is generally palliative. Depending on the size of the tumor, RFA can shrink or kill the tumor, extending the patient's survival time and greatly improving their quality of life while living with cancer.
Microwave ablation utilizes electromagnetic microwaves to agitate the water molecules in the tumor and surrounding tissue, ultimately reversing the cells' polarity. This change in polarity causes the cells to rotate back and forth, causing friction and heat, which then kill the cells (coagulation necrosis).


Related Links:
Rhode Island Hospital